The cardiovascular (CV) implications of smoking remain a critical concern for clinicians globally. While complete cessation is the gold standard, many patients consider a tobacco harm reduction strategy by switching to non-combustible alternatives. This clinical review examines whether electronic cigarettes (e-cigarettes) and heated tobacco products (HTPs) truly offer a safer profile compared to traditional combustible cigarettes.

Extensive evidence suggests that switching significantly reduces exposure to harmful and potentially harmful constituents (HPHCs). For instance, carbon monoxide levels and carcinogen biomarkers improve markedly after the transition. These improvements often mirror those observed in individuals who achieve total smoking cessation. Furthermore, short-term clinical studies reveal favorable shifts in vascular health markers.

Evaluating the Tobacco Harm Reduction Strategy

Users who transition to these products often show improved endothelial function and reduced arterial stiffness. Moreover, oxidative stress markers tend to decrease when smokers move to combustion-free options. However, it is essential to note that nicotine-containing products still exert acute effects on heart rate and blood pressure. Long-term epidemiological data suggest a lower incidence of major adverse cardiovascular events (MACEs) in exclusive users compared to continued smokers. Nevertheless, the heterogeneity in device design and usage patterns makes definitive conclusions difficult. Therefore, healthcare providers should view these as transitional tools rather than entirely risk-free products.

Frequently Asked Questions

Are e-cigarettes completely safe for the heart?

No, they are not risk-free. While they reduce exposure to many toxins found in smoke, nicotine still causes acute cardiovascular stress, and researchers are still investigating the long-term effects.

How do HTPs differ from traditional cigarettes?

HTPs heat tobacco without burning it. This prevents combustion and significantly lowers the levels of inhaled carbon monoxide and toxic carcinogens compared to regular smoking.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Festinese S et al. Cardiovascular effects of electronic cigarettes and heated tobacco products: Clinical evidence from a narrative review. Adv Clin Exp Med. 2026 Apr 02. doi: 10.17219/acem/217292. PMID: 41926775.

Tobacco Induced Diseases. Electronic cigarettes and cardiovascular diseases: An updated systematic review and network meta-analysis. Tob Induc Dis. 2025 Sep 05. doi: 10.18332/tid/191567.

Andreozzi P et al. Heated tobacco products vs conventional cigarettes: a scoping review of cardiovascular and respiratory clinical outcomes. Intern Emerg Med. 2026 Jan. doi: 10.1007/s11739-025-03821-w.